Explore cutting-edge peptide therapeutics for metabolic disorders, including GLP-1 agonists, dual and triple receptor agonists, and innovative treatments for obesity and diabetes.
Overview
Recent advancements in peptide therapies have led to the development of three promising treatments for obesity and type 2 diabetes: tirzepatide, retatrutide, and cagrilintide.
Tirzepatide
A dual GIP/GLP-1 receptor agonist that significantly improves glycemic control and promotes substantial weight loss in patients with type 2 diabetes.
Retatrutide
An innovative triple-agonist peptide that targets GIP, GLP-1, and glucagon receptors, offering significant weight loss and metabolic benefits for patients with obesity and type 2 diabetes.
Cagrilintide
A cutting-edge, long-acting amylin receptor agonist that offers significant weight loss benefits and improved metabolic control for patients with obesity and type 2 diabetes.